文献速递复苏、休克与脓毒症消化、代谢与肾脏急症

疑似感染急诊患者疾病进展的早期识别:多中心衍生与验证研究

The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study.
PubMed 文献 · Crit Care · 2019-02-08
一句话结论在急诊疑似感染患者中,血标志物MR-proADM预测28天死亡与住院需求的准确性最高,高值(≥1.54 nmol/L)者即使其他标志物或评分低,进展风险仍显著升高。

本研究为观察性衍生队列并在九个急诊科进行独立验证,旨在寻找能评估疑似感染急诊患者疾病进展与住院决策的血标志物(MR-proADM、PCT、乳酸、CRP)或临床评分(SIRS、SOFA、qSOFA、NEWS、CRB-65)。衍生队列1175例、验证队列896例,28天死亡率分别为7.1%和5.0%,住院率分别为77.9%和76.2%。MR-proADM在两个队列中预测28天死亡和住院需求的准确性最高;MR-proADM≥1.54 nmol/L且其他标志物或评分低的亚组,住院时间、ICU入住率、死亡风险和疾病进展事件均显著高于MR-proADM<1.54 nmol/L的相似亚组。采用衍生队列得出的MR-proADM截断值<0.87 nmol/L可促进门诊治疗(两队列分别为15.0%和16.6%),再入院率降低且无死亡。

要点

  • 急诊疑似感染患者中,MR-proADM预测28天死亡和住院需求的准确性高于PCT、乳酸、CRP及SIRS、SOFA、qSOFA、NEWS、CRB-65评分。
  • MR-proADM≥1.54 nmol/L且SOFA<2分者的死亡风险HR为45.5(95%CI 10.0-207.6),显著高于MR-proADM<1.54 nmol/L的相似亚组。
  • MR-proADM≥1.54 nmol/L且qSOFA<2分者死亡风险HR为23.4(95%CI 11.1-49.3),NEWS<4分者HR为32.6(95%CI 9.4-113.6)。
  • MR-proADM≥1.54 nmol/L且PCT<0.25 ng/mL、乳酸<2.0 mmol/L或CRP<67 mg/L的亚组,住院时间更长、ICU入住率更高、疾病进展事件更多(p<0.001)。
  • 采用MR-proADM截断值<0.87 nmol/L筛选门诊治疗,衍生队列15.0%、验证队列16.6%的患者符合,再入院率降低且无死亡。

适用人群与场景

  • 就诊于急诊科且疑似感染的患者,来自九个急诊科。
  • 衍生队列1175例,验证队列896例。

诊断标准与关键阈值

  • 疾病进展复合终点:28天死亡、ICU入住和住院>10天。
  • 高MR-proADM定义为≥1.54 nmol/L;低MR-proADM定义为<1.54 nmol/L。
  • 低标志物阈值:PCT<0.25 ng/mL、乳酸<2.0 mmol/L、CRP<67 mg/L。
  • 低临床评分阈值:SOFA<2分、qSOFA<2分、NEWS<4分、CRB-65<2分。
  • 门诊治疗筛选截断值:MR-proADM<0.87 nmol/L。

红旗征与不能漏的情况

  • MR-proADM≥1.54 nmol/L且SOFA<2分、qSOFA<2分或NEWS<4分时,死亡风险显著升高(HR分别为45.5、23.4、32.6),需警惕疾病进展。
  • MR-proADM≥1.54 nmol/L且PCT<0.25 ng/mL、乳酸<2.0 mmol/L或CRP<67 mg/L时,住院时间更长、ICU入住率更高、疾病进展事件更多(p<0.001)。

研究设计与关键结果

  • 研究类型:观察性衍生队列,并在九个急诊科进行独立验证分析;衍生队列1175例,验证队列896例。
  • 28天死亡率:衍生队列7.1%,验证队列5.0%;住院率:衍生队列77.9%,验证队列76.2%。
  • MR-proADM在两个队列中预测28天死亡和住院需求的准确性最高。
  • 与低MR-proADM(<1.54 nmol/L)相似亚组相比,高MR-proADM(≥1.54 nmol/L)且低SOFA(<2分)、低qSOFA(<2分)、低NEWS(<4分)亚组的死亡风险HR分别为45.5(95%CI 10.0-207.6)、23.4(95%CI 11.1-49.3)、32.6(95%CI 9.4-113.6);上述亚组住院时间更长(p<0.001)、ICU入住率更高(p<0.001)、疾病进展事件更多(p<0.001)。
  • 采用MR-proADM截断值<0.87 nmol/L筛选门诊治疗,衍生队列15.0%、验证队列16.6%的患者符合,再入院率降低且无死亡。

证据类型、等级与局限

  • 证据类型:观察性衍生与验证研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,将MR-proADM纳入早期脓毒症管理方案可能有助于快速决策,以启动、升级或强化早期治疗策略,或识别适合安全门诊治疗的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There is a lack of validated tools to assess potential disease progression and hospitalisation decisions in patients presenting to the emergency department (ED) with a suspected infection. This study aimed to identify suitable blood biomarkers (MR-proADM, PCT, lactate and CRP) or clinical scores (SIRS, SOFA, qSOFA, NEWS and CRB-65) to fulfil this unmet clinical need.

METHODS: An observational derivation patient cohort validated by an independent secondary analysis across nine EDs. Logistic and Cox regression, area under the receiver operating characteristic (AUROC) and Kaplan-Meier curves were used to assess performance. Disease progression was identified using a composite endpoint of 28-day mortality, ICU admission and hospitalisation > 10 days.

RESULTS: One thousand one hundred seventy-five derivation and 896 validation patients were analysed with respective 28-day mortality rates of 7.1% and 5.0%, and hospitalisation rates of 77.9% and 76.2%. MR-proADM showed greatest accuracy in predicting 28-day mortality and hospitalisation requirement across both cohorts. Patient subgroups with high MR-proADM concentrations (≥ 1.54 nmol/L) and low biomarker (PCT < 0.25 ng/mL, lactate < 2.0 mmol/L or CRP < 67 mg/L) or clinical score (SOFA < 2 points, qSOFA < 2 points, NEWS < 4 points or CRB-65 < 2 points) values were characterised by a significantly longer length of hospitalisation (p < 0.001), rate of ICU admission (p < 0.001), elevated mortality risk (e.g. SOFA, qSOFA and NEWS HR [95%CI], 45.5 [10.0-207.6], 23.4 [11.1-49.3] and 32.6 [9.4-113.6], respectively) and a greater number of disease progression events (p < 0.001), compared to similar subgroups with low MR-proADM concentrations (< 1.54 nmol/L). Increased out-patient treatment across both cohorts could be facilitated using a derivation-derived MR-proADM cut-off of < 0.87 nmol/L (15.0% and 16.6%), with decreased readmission rates and no mortalities.

CONCLUSIONS: In patients presenting to the ED with a suspected infection, the blood biomarker MR-proADM could most accurately identify the likelihood of further disease progression. Incorporation into an early sepsis management protocol may therefore aid rapid decision-making in order to either initiate, escalate or intensify early treatment strategies, or identify patients suitable for safe out-patient treatment.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Saeed K, Wilson DC, Bloos F, et al. The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study. Crit Care. 2019. PMID: 30736862. doi:10.1186/s13054-019-2329-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。